Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 14/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRE | P78334 | 1/20 | 0.32 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.32 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.32 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL22655475 | 0.88 | KDM1A (0.36) | KDM1APKMDPP8GABRPGABRD | |
| Oxalic Acid SCHEMBL29212837 | 0.81 | GABRP (0.37) | GABRPGABRDGABRA1TSHRGABRB1 | |
| Trifluoroacetic Acid SCHEMBL4307037 | 0.80 | PKM (0.36) | KDM1APKMGABRPGABRDGABRA1 | |
| Acetic Acid SCHEMBL29212835 | 0.79 | GABRP (0.35) | GABRPGABRDGABRA1TSHRGABRB1 | |
| Trifluoroacetic Acid SCHEMBL23163788 | 0.79 | KDM1A (0.33) | KDM1APKMDPP8 | |
| Trifluoroacetic Acid SCHEMBL3471327 | 0.78 | TSHR (0.38) | KDM1APKMGABRPGABRDGABRA1 | |
| Trifluoroacetic Acid SCHEMBL4391008 | 0.78 | TSHR (0.38) | KDM1APKMGABRPGABRDGABRA1 | |
| SCHEMBL273897 | 0.75 | — | — | |
| Trifluoroacetic Acid SCHEMBL9425624 | 0.75 | TSHR (0.34) | KDM1APKMGABRPGABRDGABRA1 | |
| Trifluoroacetic Acid SCHEMBL31708307 | 0.75 | PKM (0.33) | KDM1APKMGABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018202537-A1 | PROCESS FOR THE PREPARATION OF AN AZOLIC DERIVATIVE | SEEGPHARM SA (CH) | 2018-11-08 | — | — | WO | claimed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-118119595-A | Compounds and compositions for the treatment of diseases associated with STING activity | 艾福姆德尤股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117062814-A | Compounds that rapidly accelerate fibrosarcoma protein degradation and related methods of use | 阿维纳斯运营公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-4204418-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | Arvinas Operations, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-06-01 | — | — | US | disclosed |
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-16 | — | — | US | disclosed |
| EP-2612859-B1 | METHOD FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVE | KAKEN PHARMA CO LTD (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-8871942-B2 | Process for producing 1-triazole-2-butanol derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| EP-2612859-A1 | METHOD FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVE | Kaken Pharmaceutical Co., Ltd. (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-20130150586-A1 | PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| CN-103080100-A | Process for producing 1-triazole-2-butanol derivative | KAKEN PHARMA CO LTD | 2013-05-01 | — | — | CN | disclosed |
| EP-1756069-A4 | HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1756069-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7115601-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-03 | — | — | US | disclosed |
| WO-2005115398-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050261322-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230081501-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | KDM1A 2231/4885PKM 4050/4885DPP8 4313/4885 |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | KDM1A 4356/4885PKM 4566/4885DPP8 2551/4885 |
| US-12180193-B2 | Accelerating fibrosarcoma protein degrading compounds and associated methods of use | CRBN, RBX1, ARAF | KDM1A 2178/4885PKM 4098/4885DPP8 4316/4885 |
| US-20250236612-A1 | RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE | CRBN, RBX1, ARAF | KDM1A 2231/4885PKM 4050/4885DPP8 4313/4885 |
| US-20050261322-A1 | HIV integrase inhibitors | TYMP, PAICS, TYMS | KDM1A 2644/4885PKM 3820/4885DPP8 399/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | KDM1A 3640/4885PKM 3505/4885DPP8 1457/4885 |
| US-20230167057-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | KDM1A 3640/4885PKM 3505/4885DPP8 1457/4885 |
| US-20130150586-A1 | PROCESS FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVES | CACNA1I, MED1, ADH1A | KDM1A 539/4885PKM 3888/4885DPP8 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.